Non-Autoimmune Hemolytic Anemia with Clostridium Ramosum Bacteremia

por Al-kali, Aref, Oswal, Alok, Tfayli, Arafat
Publicado 2008

Critical appraisal of the role of rituximab in the treatment of patients with previously untreated or treated chronic lymphocytic leukemia (CLL)

por Al-Kali, Aref, Wierda, William, Keating, Michael, O’Brien, Susan
Publicado 2010

The Role of Monoclonal Antibodies in the Management of Leukemia

por Al-Ameri, Ali, Cherry, Mohamad, Al-Kali, Aref, Ferrajoli, Alessandra
Publicado 2010

An Erythrocytosis-Associated Mutation in the Zinc Finger of PHD2 Provides Insights into Its Binding of p23

por Song, Daisheng, Guan, Wei, Coon, Lea M, Al-Kali, Aref, Oliveira, Jennifer L, Lee, Frank S
Publicado 2019

Determinants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS- 911543 JAK2 inhib...

por Gangat, Naseema, Begna, Kebede H., Al-Kali, Aref, Hogan, William, Litzow, Mark, Pardanani, Animesh, Tefferi, Ayalew
Publicado 2023

A nucleolin-DNMT1 regulatory axis in acute myeloid leukemogenesis

por Shen, Na, Yan, Fei, Pang, Jiuxia, Wu, Lai-Chu, Al-Kali, Aref, Litzow, Mark R., Liu, Shujun
Publicado 2014

Busulfan Treatment for Myeloproliferative Disease may Reduce Injection Burden in Vascular Endothelial Growth Factor-Driven Retinopathy

por Dalvin, Lauren A., Olsen, Timothy W., Bakri, Sophie J., McCullough, Kristen, Tefferi, Ayalew, Al-Kali, Aref
Publicado 2022

A systematic review and network meta-analysis comparing azacitidine and decitabine for the treatment of myelodysplastic syndrome

por Almasri, Jehad, Alkhateeb, Hassan B., Firwana, Belal, Sonbol, Mohamad Bassam, Damlaj, Moussab, Wang, Zhen, Murad, M. Hassan, Al-Kali, Aref
Publicado 2018

A dynamic N(6)-methyladenosine methylome regulates intrinsic and acquired resistance to tyrosine kinase inhibitors

por Yan, Fei, Al-Kali, Aref, Zhang, Zijie, Liu, Jun, Pang, Jiuxia, Zhao, Na, He, Chuan, Litzow, Mark R., Liu, Shujun
Publicado 2018

Erythrocytosis associated with EPAS1(HIF2A), EGLN1(PHD2), VHL, EPOR or BPGM mutations: the Mayo Clinic experience

por Gangat, Naseema, Oliveira, Jennifer L., Porter, Tavanna R, Hoyer, James D., Al-Kali, Aref, Patnaik, Mrinal M, Pardanani, Animesh, Tefferi, Ayalew
Publicado 2022

Liposomal bortezomib is active against chronic myeloid leukemia by disrupting the Sp1-BCR/ABL axis

por Yang, Xiaojuan, Pang, Jiuxia, Shen, Na, Yan, Fei, Wu, Lai-Chu, Al-Kali, Aref, Litzow, Mark R., Peng, Yong, Lee, Robert J., Liu, Shujun
Publicado 2016

Classification of Monocytes, Promonocytes and Monoblasts Using Deep Neural Network Models: An Area of Unmet Need in Diagnostic Hematopathology

por Osman, Mazen, Akkus, Zeynettin, Jevremovic, Dragan, Nguyen, Phuong L., Roh, Dana, Al-Kali, Aref, Patnaik, Mrinal M., Nanaa, Ahmad, Rizk, Samia, Salama, Mohamed E.
Publicado 2021

Biallelic inactivation of the retinoblastoma gene results in transformation of chronic myelomonocytic leukemia to a blastic plasmacytoid dendritic cell neoplasm: shared clonal orig...

por Patnaik, Mrinal M., Lasho, Terra, Howard, Matthew, Finke, Christy, Ketterling, Rhett L., Al-Kali, Aref, Pardanani, Animesh, Droin, Nathalie, Gangat, Naseema, Tefferi, Ayalew, Solary, Eric
Publicado 2018

S263: CYTOPENIAS, AGE AND CAR-HEMATOTOX SCORE PREDICT THE DEVELOPMENT OF POST CAR T-CELL THERAPY-RELATED MYELOID NEOPLASMS

por Gurney, Mark, Alkhateeb, Hassan, Shah, Syed, Bansal, Radhika, Hathcock, Matthew, Rosenthal, Allison, Kharfan-Dabaja, Mohamed, Kourelis, Taxiarchis, Patnaik, Mrinal, Chen, Dong, Al-Kali, Aref, Kenderian, Saad, Lin, Yi, Shah, Mithun
Publicado 2023

The Hedgehog pathway as targetable vulnerability with 5-azacytidine in myelodysplastic syndrome and acute myeloid leukemia

por Tibes, Raoul, Al-Kali, Aref, Oliver, Gavin R, Delman, Devora H, Hansen, Nanna, Bhagavatula, Keerthi, Mohan, Jayaram, Rakhshan, Fariborz, Wood, Thomas, Foran, James M., Mesa, Ruben A., Bogenberger, James M.
Publicado 2015

Histone deacetylase inhibitors reduce differentiating osteoblast-mediated protection of acute myeloid leukemia cells from cytarabine

por Sterner, Rosalie M., Kremer, Kimberly N., Al-Kali, Aref, Patnaik, Mrinal M., Gangat, Naseema, Litzow, Mark R., Kaufmann, Scott H., Westendorf, Jennifer J., van Wijnen, Andre J., Hedin, Karen E.
Publicado 2017

Outcomes of allogeneic transplant in patients with DDX41 mutated myelodysplastic syndrome and acute myeloid leukemia

por Baranwal, Anmol, Nanaa, Ahmad, Viswanatha, David, He, Rong, Foran, James, Badar, Talha, Hogan, William J., Litzow, Mark R., Shah, Mithun Vinod, Patnaik, Mrinal M., Al-Kali, Aref, Alkhateeb, Hassan B.
Publicado 2022

Molecular predictors of response to venetoclax plus hypomethylating agent in treatment-naïve acute myeloid leukemia

por Gangat, Naseema, Johnson, Isla, McCullough, Kristen, Farrukh, Faiqa, Al-Kali, Aref, Alkhateeb, Hassan, Begna, Kebede, Mangaonkar, Abhishek, Litzow, Mark, Hogan, William, Shah, Mithun, Patnaik, Mrinal, Pardanani, Animesh, Tefferi, Ayalew
Publicado 2022

Momelotinib therapy for myelofibrosis: a 7-year follow-up

por Tefferi, Ayalew, Barraco, Daniela, Lasho, Terra L., Shah, Sahrish, Begna, Kebede H., Al-Kali, Aref, Hogan, William J., Litzow, Mark R., Hanson, Curtis A., Ketterling, Rhett P., Gangat, Naseema, Pardanani, Animesh
Publicado 2018

Clinical outcome of myelodysplastic syndrome progressing on hypomethylating agents with evolving frontline therapies: continued challenges and unmet needs

por Ghorab, Ahmad, Al-Kali, Aref, Elliot, Michelle, Gangat, Naseema, Alkhateeb, Hasan, Shah, Mithun, Liu, Yuanhang, Yi, Cecilia Arana, Murthy, Hemant, Kharfan-Dabaja, Mohamed, Tefferi, Ayalew, Patnaik, Mrinal, Litzow, Mark, Badar, Talha
Publicado 2022